

	Israeli Prostate Study		WAS*		OR	95% CI
Mutation	N	%	N	%		
<i>BRCA1</i>						
185delAG	14	1.49	6	0.7	2.18	0.78-6.96
5382insC	2	0.21	2	0.2	0.93	0.07-12.82
<i>BRCA2</i>						
6174delT	14	1.49	5	0.6	2.62	0.89-9.34
Total Positive	30	3.19	13	1.49	2.18†	1.09-4.43
Total	940		872			
	Israeli Prostate Study		MECC*		OR	95% CI
Mutation	N	%	N	%		
<i>BRCA1</i>						
185delAG	14	1.49	2	0.42	3.55	0.80-15.70
5382insC	2	0.21	1	0.21	1.00	0.09-11.1
<i>BRCA2</i>						
6174delT	14	1.49	5	1.06	1.41	0.50-3.94
Total Positive	30	3.19	8	1.69	1.91	0.87-4.20
Total	940		472			
	Israeli Prostate Study		WAS + MECC*		OR	95% CI
Mutation	N	%	N	%		
<i>BRCA1</i>						
185delAG	14	1.49	8	0.59	2.52	1.05-6.04
5382insC	2	0.21	3	0.22	0.95	0.16-5.72
<i>BRCA2</i>						
6174delT	14	1.49	10	0.74	2.02	0.89-4.56
Total Positive	30	3.19	21	1.56	2.08†	1.18-3.65
Total	940		1344			

*Ashkenazi Jewish male controls 50 years and above without history of prostate cancer.

†p<0.05